Is AOD-9604 Legal in Wisconsin? Federal Rules, State Law, and How to Get It

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone, specifically amino acids 176 to 191. It does not bind the growth hormone receptor in the same way full-length HGH does, and it carries no meaningful insulin-like growth factor-1 (IGF-1) stimulation at studied doses. The peptide was originally developed by Monash University and later licensed to Metabolic Pharmaceuticals for obesity research in the early 2000s.

Mechanism of Action

AOD-9604 is thought to stimulate lipolysis and inhibit lipogenesis through a mechanism that may involve beta-3 adrenergic pathways rather than IGF-1 signaling. A 2001 paper published in the American Journal of Physiology showed that the fragment reduced body weight in obese Zucker rats without producing hyperglycemia or IGF-1 elevation, distinguishing it from full-length growth hormone [1]. That mechanistic separation is part of why researchers and compounding pharmacies treat it differently from HGH itself.

Human Trial History

Metabolic Pharmaceuticals ran a series of human trials in the early 2000s. A 12-week, randomized, placebo-controlled Phase IIb study (N=300) tested oral AOD-9604 at doses ranging from 1 mg to 9 mg daily. Subjects receiving the 1 mg dose lost a mean of 2.1 kg more than placebo at 12 weeks, though the difference narrowed at higher doses and failed to reach the primary endpoint in a subsequent Phase III effort [2]. The FDA never granted approval. The compound also entered Australian trials for osteoarthritis (AUST 99/1939), where its cartilage-regenerative properties were investigated, but no regulatory body has issued a finished-drug approval for any indication.

Because no approved New Drug Application (NDA) or Biologics License Application (BLA) exists, AOD-9604 cannot be sold as a finished pharmaceutical product in the United States.

Federal Legal Framework: FDA Rules That Apply in Wisconsin

Federal law governs drug manufacturing and compounding nationwide, which means the FDA's position on AOD-9604 directly shapes what Wisconsin practitioners and pharmacies can do.

The 503A Bulk Substances List

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound drugs for individual patients on the basis of a valid prescription, provided the bulk substances used meet specific criteria [3]. The FDA maintains a list of bulk substances that compounding pharmacies may use (the "503A bulks" list) and a separate list of substances that may not be used in compounding.

AOD-9604 has not been placed on the affirmative 503A "may use" list. The FDA's Division of Pharmaceutical Quality Operations has flagged peptides not on that affirmative list as outside the scope of lawful 503A compounding. Pharmacies compounding AOD-9604 for individual patients technically operate in a space the FDA has not sanctioned, exposing both the pharmacy and the prescriber to regulatory risk [3].

The 503B Outsourcing Facility Standard

Section 503B of the FD&C Act created a separate category of "outsourcing facilities" that can compound larger batches without individual prescriptions, provided they register with the FDA and follow Current Good Manufacturing Practice (CGMP) standards [4]. The FDA has stated that 503B facilities may only compound using bulk substances that appear on the agency's 503B bulks list. AOD-9604 does not appear on that list either.

A 2022 FDA guidance document on bulk drug substances for outsourcing facilities reinforced that compounding a substance not on the 503B list is considered production of an unapproved new drug [4]. That matters for Wisconsin patients because many national compounding pharmacies serving telehealth practices operate as 503B facilities.

DEA Controlled Substance Status

AOD-9604 is not scheduled under the Controlled Substances Act [5]. It carries no DEA classification as of January 2025, meaning possession by an individual is not a federal criminal offense the way possession of Schedule II substances would be. Prescribers do not need a separate DEA registration line to prescribe it. Absence of DEA scheduling does not mean absence of FDA oversight of manufacturing and sale.

Research Use Exception

AOD-9604 may be used legally in the United States under an Investigational New Drug (IND) application filed with the FDA [6]. Academic institutions and pharmaceutical companies that hold an active IND can administer it to human subjects under IRB-approved protocols. No active IND for AOD-9604 in weight loss is publicly listed in the ClinicalTrials.gov database as of early 2025, though individual investigators may hold private INDs.

Wisconsin State Law: What the State Adds (and Does Not Add)

Wisconsin does not have a statute that names AOD-9604 or bans peptide compounds as a class. The relevant Wisconsin law is primarily found in Chapter 450 of the Wisconsin Statutes, which governs pharmacy practice, and Chapter 448, which governs the practice of medicine.

Wisconsin Pharmacy Examining Board

The Wisconsin Pharmacy Examining Board, operating under the Wisconsin Department of Safety and Professional Services (DSPS), licenses pharmacies and pharmacists in the state. Wisconsin Statute § 450.11 governs prescription drug dispensing and compounding. State rules incorporate federal standards by reference: a Wisconsin pharmacy that compounds a drug product in violation of federal FD&C Act requirements may also be in violation of Wisconsin pharmacy law and subject to license discipline [7].

Practically, this means a Wisconsin compounding pharmacy that compounds AOD-9604 using bulk API that has not been placed on the FDA 503A affirmative list is taking on both federal and potential state regulatory risk simultaneously.

Wisconsin Medical Practice Act

Chapter 448 of the Wisconsin Statutes defines the lawful practice of medicine. Physicians licensed in Wisconsin retain broad prescriptive authority for substances not listed as controlled, but that authority does not override FDA manufacturing and compounding regulations [8]. A Wisconsin physician can write a prescription for AOD-9604, but the pharmacy filling that prescription must still comply with FDA compounding rules. The prescription itself is not illegal; the compounding context is where legal exposure concentrates.

No Wisconsin-Specific Peptide Ban

Several states have passed laws specifically restricting performance-enhancing peptides or requiring registration of novel compounds. Wisconsin has not done so for AOD-9604 as of January 2025. Residents should confirm current DSPS guidance directly, because state agency positions can change between publication and the date of this article [7].

How AOD-9604 Compares to Other Peptides Under Federal Law

Understanding AOD-9604's status is easier when placed alongside other peptides that have received definitive FDA action.

Semaglutide and Tirzepatide

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved drugs. During the shortage period, the FDA allowed 503A and 503B compounding of these molecules under specific conditions outlined in shortage guidance [9]. AOD-9604 has never had an approved product, so no shortage-based compounding carve-out exists.

BPC-157

BPC-157 shares a similar federal status with AOD-9604: no FDA approval, not on the 503A affirmative list, and under ongoing FDA scrutiny. The FDA issued a statement in 2023 indicating that BPC-157 cannot be compounded lawfully under 503A or 503B [10]. That regulatory action is a signal of the direction FDA enforcement may take with other unapproved peptides including AOD-9604.

Sermorelin

Sermorelin has FDA-approved status as a finished drug (for growth hormone deficiency diagnosis), which means it appears on the 503A bulks list and can be compounded lawfully by state-licensed pharmacies with a valid prescription. AOD-9604 does not share that status [11].

The table below summarizes the federal compounding status of four commonly prescribed peptides, which the HealthRX medical team compiled from FDA bulk substances lists and agency guidance as of January 2025.

| Peptide | FDA-Approved Product | On 503A Bulks List | On 503B Bulks List | DEA Scheduled | |---|---|---|---|---| | Semaglutide | Yes (Wegovy, Ozempic) | Shortage exception only | Shortage exception only | No | | Sermorelin | Yes (Geref, discontinued) | Yes | Limited | No | | BPC-157 | No | No (banned) | No | No | | AOD-9604 | No | Not listed (not permitted) | Not listed | No |

Practical Pathways: How Wisconsin Patients Can Access AOD-9604

The legal complexity does not make AOD-9604 completely inaccessible in Wisconsin, but it does narrow the options and create real risk for both patients and providers.

Telehealth Prescribing Within Wisconsin

A physician or advanced practice provider holding a Wisconsin license and a valid DEA registration (for other controlled substances in the practice) may conduct a telehealth consultation and prescribe AOD-9604. The Ryan Haight Online Pharmacy Consumer Protection Act requires that controlled substances not be prescribed via telemedicine without a prior in-person evaluation, but AOD-9604 is not a controlled substance, so that requirement does not apply directly [12].

The prescriber still carries professional liability if the prescription is filled by a pharmacy that is not complying with FDA compounding rules. Patients and prescribers should verify that any compounding pharmacy is state-licensed in Wisconsin and uses AOD-9604 bulk API from an FDA-registered supplier.

What to Ask a Compounding Pharmacy

Patients and clinicians evaluating a compounding pharmacy for AOD-9604 should ask for documentation on four specific points.

First, the pharmacy should confirm its state license in Wisconsin or confirm it holds an out-of-state pharmacy permit from the Wisconsin DSPS. Second, the pharmacy should disclose whether it operates as a 503A or 503B facility. Third, it should provide a Certificate of Analysis (COA) from an accredited third-party lab for the bulk AOD-9604 API, confirming identity, purity, and absence of endotoxins. Fourth, the pharmacy should acknowledge in writing its understanding of the FDA's current position on unapproved peptide compounding [3].

International Sources and Legal Risk

Some Wisconsin residents attempt to obtain AOD-9604 from international suppliers or research chemical vendors marketing it as "not for human use." Importing an unapproved drug for personal use from abroad is generally prohibited under 21 U.S.C. § 331 and FDA import regulations [13]. The FDA has authority to seize shipments at the border. Personal-use imports exist in a gray zone where enforcement is inconsistent, but the legal risk to the importer is real.

Research chemical suppliers that sell AOD-9604 labeled "for laboratory use only" are not exempt from FDA oversight when the product is intended for human administration. Purchasing from these sources carries safety risks beyond legal ones: without pharmaceutical-grade manufacturing, contamination and inaccurate dosing are documented concerns in the peptide gray market [14].

Dosing Context: What Clinical Data Exists

Because AOD-9604 is not FDA-approved, no official prescribing label exists. The human trial data that does exist provides a starting point for understanding studied doses, though clinicians must use professional judgment.

Subcutaneous Injection Protocols

The Phase IIb human trials used oral delivery, but the compounding market predominantly offers AOD-9604 as a subcutaneous injectable. Injectable doses studied in clinical settings typically range from 250 mcg to 500 mcg per day, administered before the first meal of the day or before exercise. A 2004 report in the International Journal of Obesity noted that subcutaneous administration in animal models produced lipolytic effects at doses as low as 25 mcg/kg [15]. Human equivalent dosing at these thresholds has not been established in published randomized controlled trials.

Safety Profile From Available Data

The Phase IIb trial (N=300, 12 weeks) reported no significant adverse events distinguishable from placebo at doses up to 9 mg oral daily [2]. No serious cardiovascular, hepatic, or renal events were attributed to AOD-9604 in published trial summaries. The compound did not suppress the hypothalamic-pituitary-gonadal axis in the studied populations, which differentiates it from exogenous HGH. Long-term safety data beyond 12 weeks in humans is not available from peer-reviewed published trials.

Monitoring Recommendations

Given the absence of approved labeling, Wisconsin clinicians who choose to prescribe AOD-9604 off the compounding market should consider baseline and follow-up fasting glucose, IGF-1 (to confirm no unexpected IGF-1 elevation), and a lipid panel at 3-month intervals. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency provides a reference framework for IGF-1 monitoring in patients on growth hormone-axis peptides, even though AOD-9604 is not an HGH secretagogue in the traditional sense [16].

Enforcement Climate and Practical Risk Assessment

The FDA's enforcement posture toward unapproved peptides has tightened since 2020. The agency issued warning letters to multiple compounding pharmacies between 2020 and 2024 for compounding substances not on the 503A affirmative list, including peptides such as BPC-157, TB-500 (thymosin beta-4), and melanotan II [10]. AOD-9604 has not been the subject of a named FDA warning letter as of January 2025, but the regulatory trajectory is clear.

Wisconsin pharmacies and prescribers operating in this space should monitor FDA enforcement actions on an ongoing basis. The FDA's Inspections, Compliance, Enforcement, and Criminal Investigations (ICECI) database is publicly accessible and lists warning letters and injunctions against compounding pharmacies [17].

For patients, the practical risk of receiving a compounded AOD-9604 product is primarily a quality and efficacy risk rather than a criminal one, given the absence of DEA scheduling. Physicians, however, may face state medical board scrutiny if they prescribe a compound that a federal agency has flagged as unlawfully compounded, particularly if a patient experiences an adverse event.